Get started

Stocktrading

LSXMA - Good Upside PotentialLSXMA broke the parallel channel that was holding the price since November 2022 after making a double bottom with the March 2020 low, I also liked the fact that the 2D SMMA was also broken, after having served as resistance since January 2023 and it is currently retesting it, and as if that wasn't enough to be bullish, LSXMA had a bullish divergence on the RSI on the weekly time frame. I believe that if the LSXMA price holds above the parallel channel (SMMA), it could be the beginning of a new up trend, and could give good gains in the medium term.
LLong
by The_Trading_Wizard_
CSE - Monthly ChartCriteria for another Bull market in Stock market of Sri lanka 1. Need to close few more Green candles above 9150 in monthly chart & It should protect 21 EMA in monthly chart 2. RSI should be more than 50 in monthly chart 3. Finally monthly candles should break strong resistance level 10650 Disclaimer: The information and analysis provided in this publication are for educational purposes only and should not be construed as financial advice or recommendations to buy, sell, or hold any securities. The author and TradingView are not responsible for any investment decisions made based on the content presented herein. Always consult a financial professional before making any investment decisions.
CSELK:ASILong
by rukshan2102
Easing Inflation Rate Spurs Optimism for a Bullish Trend?Hi Realistic Traders. Here's my price action analysis on the S&P 500! The CBOE:SPX has convincingly breached the double bottom, presenting a compelling signal for a potential bullish reversal. The price trajectory exhibits a sustained upward movement, concurrently shaping a continuation pattern recognized as the Descending Broadening Wedge Pattern. As this pattern unfolds, a subsequent breakout from the descending broadening wedge provides robust confirmation of a conceivable upward trajectory toward the specified target area. Beyond the prism of price dynamics, the oscillator has undergone a significant golden cross, adding another layer of confidence to the outlook and signaling the potential for a bullish market trend. It is essential to note that the analysis will no longer hold validity once the target/support area is reached. Recent Announcement of the Inflation Data - In October 2023, the annual inflation rate in the United States decelerated to 3.2%, marking a decrease from 3.7% observed in both September and August. This figure also fell below market forecasts of 3.3%. - The annual core consumer price inflation rate in the United States, excluding volatile items such as food and energy, exhibited a marginal decline to an over two-year low of 4% in October 2023, down from 4.1% in the preceding month. Contrary to market expectations, which anticipated stability at 4.1%. - The unexpected deceleration in inflation has fostered the anticipation that the Federal Reserve's assertive tightening cycle may have concluded. This development is instilling optimism for a bullish scenario in the market. Disclaimer: "Please note that this analysis is solely for educational purposes and should not be considered a recommendation to take a long or short position on CBOE:SPX ." Please support the channel by engaging with the content, using the rocket button, and sharing your opinions in the comments below!
SP:SPXLong
by financialfreedomgoals101
4
MYO a Stock I randomly pulled up and conducted some R/AR/A = Research and Analysis This stock just randomly chose to after looking at a few robotics stock. I went through a few stocks to show how I conduct my R/A and wanted to see if I could find some ideas and themes to trade. A stock that got selected was MYO. MYO is a company that sells robotic arms to people regain function in their arms and hands. Their product is called MyoPro. This stock might be able to push higher in the longer term (maybe in 2025). The technicals are not good on it. The fundamentals aren't also. And there is almost no sentiment on this stock because there is close to 0% PR on here, expect some articles talk about price movement. But, something that I saw that caught my eye is an individual in Australia used their product, was able to get their function back, and was able to benefit from the Nation Disability Insurance Scheme (NDIS) in Australia. Another that caught my eye is they are attempting to get their product approved for claims for Medicare Part B beneficiaries. If this is approved, the stock might be able to push above the $1 lvl and maybe push above the $2. So, this stock might have some promise. For now, I wouldn't get in because of the state of the economy, high inflation, and rates increasing. There are also the negatives aside from this stock almost collapsing, which is it's competitors and technologies such as Neuralink from Elon Musk. I am not in this stock and highly likely I won't get in. This is just some research I have done and I am seeing where price is going to move and to see if I am correct.
AMEX:MYOLong
by DollarSaenz
2
🛒📈 Kroger (KR) - E-commerce Investments and Growth! 💹🔍📊 Analysis: Strategic Investments: Kroger is noted for strategic investments in e-commerce. Revenue Growth: Focus on personalization, digital coupons, and strong e-commerce sales. Dividend Yield: Attractive 2.3% dividend yield outperforming the S&P 500. 📈 Bullish Sentiment: Entry: Suggested entry above the $42.00-$43.00 range. Upside Target: Aiming for an upside in the $58.00-$60.00 range. 🌐 Note: Monitor market dynamics and investment trends! 🚀📈 #Kroger #StockAnalysis #EcommerceGrowth 💰🛍
NYSE:KRLong
by Richtv_official
WALMART Forming a peak pattern. Correction possible.Walmart is technically bullish on the 1D outlook (RSI = 66.294, MACD = 1.320, ADX = 41.735) but has reached the top of the 18 month Channel Up. With the 1D RSI Double Topped inside the overbought zone, the current price is increasingly unstable and the rally since the December 11th 2023 HL unsustainable withouth a correction. The three main pullbacks inside the Channel Up have been within the -10.20% and -11.92% region. A new -10% correction would test the 0.236 Channel Fib and come close to the 1D MA200. That is our target (TP = 54.50). ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NYSE:WMTShort
by InvestingScope
1
PODDDoes look bullish. OverSold on daily, Golden pocket, KDJ Bullish. If we go past my target or hold that level and not go down, it's full continuation of Bull for this stock. Insulet (NASDAQ: PODD) stands as an innovative medical device company committed to enhancing the lives of individuals grappling with diabetes and related conditions through its groundbreaking Omnipod delivery system. PODD mission is deeply rooted in personal experiences, with many of us directly impacted by diabetes. They advocate for their customers, affectionately known as Podders, and the broader diabetes community.
NASDAQ:PODDLong
by Achilly
"PANW" Palo Alto Networks - Insider TradingPANW is being bought by US Parliament member Nancy Pelosi, she bought twice in past month. The current price is in perfect Golden Zone on Daily chart. If we go past ATH there is no actual telling where it will go up to next, we might just move sideways for now to reset RSI or even start moving up at any time. But it also might just drop down a bit. Palo Alto Networks, a cybersecurity company that provides advanced firewall and cloud security solutions. Palo Alto Networks offers a range of products and services aimed at protecting organizations from cyber threats, including next-generation firewalls, cloud security, endpoint protection, and threat intelligence services. The company is known for its focus on innovation and its commitment to helping businesses secure their digital assets against evolving cyber threats.
NASDAQ:PANWLong
by Achilly
MPW's $4.60 Price Target After Bullish BreakoutTechnical Analysis MPW has been showing some solid bullishness out of the buy zone. There has been 6 consecutive green weekly candles so far including this week. MPW is forming a bullish breakout above this light blue trendline and orange resistance zone. I think there will be a pullback at some point, but for now the trend is still bullish and $4.60 is the key price target on this move up. Medical Properties Trust (MPW): Navigating Liquidity And Strategic Asset Management Medical Properties Trust Inc. (NYSE: MPW) recently shared insights into its financial health and strategic direction during its fourth quarter 2023 earnings call. With a focus on creating significant liquidity and managing its diverse portfolio of healthcare facilities, the company outlined its plan to navigate through current challenges and capitalize on its strengths. This blog delves into the key takeaways from the earnings call, highlighting both the bullish and bearish aspects of MPW’s strategy and performance. Strategic Initiatives For Enhanced Liquidity MPW’s CEO, Edward Aldag Jr., unveiled a capital allocation strategy aimed at generating at least $2 billion in liquidity by 2024. This ambitious plan involves the sale of Australian facilities and hospitals to Prime Healthcare Services, showcasing MPW’s proactive approach to capital management. These strategic asset sales, alongside ongoing opportunities, underscore the company’s commitment to financial flexibility and growth. Addressing Challenges With Optimism Despite facing issues with Steward Health Care System’s cash collections, MPW remains optimistic. The company is actively working on re-tenanting Steward properties, reflecting confidence in its ability to manage tenant-related challenges effectively. Additionally, the improved performance of Prospect Medical Holdings adds a layer of positivity, reinforcing MPW’s diversified portfolio’s strength. A Look At The Bearish And Bullish Highlights Bearish Insights: The distressed situation with Steward has necessitated strategic re-tenanting and asset sales to ensure consistent rent payments. A significant write-down of $90 million for loans to Steward underscores the financial challenges faced. Concerns remain for an operator within the cash accounting pool, projecting no financial support due to low coverage. Bullish Perspectives: Interest from multiple potential tenants for Steward properties indicates robust demand for MPW’s assets. The company’s European and American portfolios, including Circle Health and Priory, demonstrate strong performance. Prospect Medical Holdings’ turnaround contributes to the positive outlook, highlighting potential for growth. Future Outlook And InvestingPro Insights Looking ahead, MPW is poised to achieve its strategic objectives, bolstered by a focus on sustaining community health through acute care hospitals. The company’s strategic sales and financing plans aim to navigate the complex financial landscape successfully. From an investment perspective, MPW presents a mixed bag of opportunities and challenges. According to InvestingPro data, the company boasts a market cap of $2.28 billion USD and an appealing dividend yield of 15.79%. The aggressive share buyback program and low Price / Book multiple suggest that MPW may be undervalued, offering potential for income generation and price appreciation. Conclusion Medical Properties Trust Inc. is at a pivotal point, with strategic initiatives in place to enhance liquidity and manage its portfolio effectively. While challenges remain, particularly with certain tenants, the company’s optimistic approach and strategic sales indicate a forward-looking perspective. For investors, MPW’s current valuation and dividend yield may offer attractive opportunities, especially for those focused on income generation and value investing. As MPW navigates its strategic path, its ability to adapt and capitalize on its strengths will be crucial in driving future success.
NYSE:MPWLong
by realchartchamp
NVAX Bullish Breakout After Settlement of Gavi DisputeNVAX Technical Analysis NVAX has been showing some solid bullishness since settling the Gavi dispute. NVAX is pumping out of the buy zone, and there has been a bullish breakout above the light blue resistance line. The key price target ahead is the green resistance line ($6.36), a yellow resistance zone ($8.20 to $8.46), and a red resistance line ($10.23). I have $3.54 to $3.93 as my new buy zone. I think there are likely to be more buy opportunities around there. For now the price is bullish and trending up. Novavax Reaches Settlement With Gavi, Paving The Way Forward In a significant development announced on February 22, Novavax, a key player in the COVID-19 vaccine market, has reached a settlement with Gavi, the Vaccine Alliance, resolving a contentious dispute over unfulfilled vaccine orders. This settlement marks a critical juncture for Novavax, alleviating financial uncertainties and setting the stage for future growth and collaborations. The Dispute Resolution Novavax has committed to repaying Gavi a minimum of $475 million, either in cash or through vaccine supplies, by the end of 2028. This agreement comes as a resolution to a conflict stemming from Novavax’s inability to deliver on a contract for up to 350 million doses of its COVID-19 vaccine, despite Gavi’s advance payment of $700 million in 2021 and 2022. Impact On Novavax The announcement led to a significant surge in Novavax’s stock price, which climbed by 23.2% to $4.91 following the news. This is a noteworthy rebound for the company, whose stock had previously plummeted by nearly 60% amid concerns over its operational viability. The settlement not only removes a major financial overhang but also enhances Novavax’s appeal as a business partner, according to CEO John Jacobs. Settlement Terms Under the terms of the settlement, Novavax has made an upfront payment of $75 million to Gavi, with additional payments of $80 million annually in quarterly installments scheduled through 2028. These payments can be adjusted if Gavi opts to receive vaccines instead of cash. The agreement also includes provisions for extra vaccine credits, potentially worth up to $225 million, should demand exceed the annual $80 million mark. Strategic Implications For Novavax The resolution of this dispute is pivotal for Novavax, offering a path to stabilize its financials and focus on future endeavors. CEO John Jacobs highlighted the settlement’s role in mitigating the risk of a substantial one-time payment and enabling better cash flow management. The estimated present value of the settlement ranges between $300 and $400 million, signaling a strategic financial recalibration for the company. Looking Ahead With new leadership at the helm of both Novavax and Gavi, this agreement signals a fresh start and a mutual focus on future collaborations and initiatives. Novavax is already eyeing new revenue streams, with plans to introduce a combination COVID-flu vaccine by 2026 and capitalize on a malaria vaccine developed in partnership with the Serum Institute of India. These initiatives, coupled with significant cost reductions and operational streamlining, underscore Novavax’s commitment to overcoming past challenges and seizing future opportunities. Conclusion In conclusion, the settlement between Novavax and Gavi not only resolves a major dispute but also highlights the resilience and strategic pivoting of Novavax amidst the complexities of the global vaccine landscape. As the company navigates beyond its COVID-centric phase, this development offers promising insights into its potential for innovation, growth, and partnerships in the years to come.
NASDAQ:NVAXLong
by realchartchamp